{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:47:49Z","timestamp":1778568469684,"version":"3.51.4"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":639,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:sec><jats:title>Background and purpose:<\/jats:title><jats:p>Recently, orthostatic hypotension was observed in patients with benign prostatic hyperplasia who are taking vardenafil (a PDE 5 inhibitor) and terazosin (a long acting alpha blocker). Therefore, this study was performed with DA\u20108159 (a long acting PDE 5 inhibitor) and terazosin in rats to find whether or not pharmacokinetic and pharmacodynamic interactions between the two drugs were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Experimental approach:<\/jats:title><jats:p>Pharmacokinetic and pharmacodynamic (changes in blood pressure) interactions between DA\u20108159 and terazosin were evaluated after simultaneous i.v. and p.o. administration of DA\u20108159 (30\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) and terazosin (5\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) to male Sprague\u2013Dawley rats.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key results:<\/jats:title><jats:p>After simultaneous i.v. and p.o. administration of terazosin and DA\u20108159, the total area under the plasma concentration\u2013time curve from time zero to time infinity (AUC) of terazosin became significantly greater (57.4 and 75.4% increase for i.v. and p.o. administration, respectively) than those of without DA\u20108159. The blood pressure dropping effect was considerable after simultaneous p.o. administration of DA\u20108159 and terazosin compared with each drug alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and implications:<\/jats:title><jats:p>The significantly greater AUC of terazosin after both simultaneous i.v. and p.o. administration of both drugs could be due to the hepatic (both i.v. and p.o.) and intestinal (p.o.) inhibition of the metabolism of terazosin via CYP3A1 and\/or 3A2 by DA\u20108159, since both DA\u20108159 and terazosin are metabolized via CYP3A1 and\/or 3A2 in rats. The blood pressure lowering effect after simultaneous p.o. administration of both drugs could be due to significant increase in plasma concentrations of terazosin.<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2007) <jats:bold>151<\/jats:bold>, 24\u201334. doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0707192\">10.1038\/sj.bjp.0707192<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1038\/sj.bjp.0707192","type":"journal-article","created":{"date-parts":[[2007,3,12]],"date-time":"2007-03-12T10:11:06Z","timestamp":1173694266000},"page":"24-34","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and\/or 3A2 by DA\u20108159, an erectogenic, in rats"],"prefix":"10.1111","volume":"151","author":[{"given":"E Y","family":"Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S K","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J W","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D C","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M G","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"issue":"3","key":"e_1_2_9_2_1","first-page":"S101","article-title":"Tolerance and pharmacokinetics of single\u2010dose DA\u20108159 in healthy male","volume":"14","author":"Bahng MY","year":"2002","journal-title":"Int J Impot Res"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00562058"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(76)90527-3"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00313-3"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01062108"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600680843"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600690125"},{"key":"e_1_2_9_9_1","first-page":"607","volume-title":"Cytochrome P450 Structure Mechanism, and Biochemistry","author":"Correia MA","year":"1995"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018943613122"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0076-6879(95)49031-0"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061729"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/01480548408994211"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.01.001"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6468(02)41007-7"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250400010898"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061772"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2005.030.07.918084"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.453"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.07.011"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000142687.75577.e4"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01059061"},{"key":"e_1_2_9_24_1","volume-title":"Clinical Biomedical and Hematological Reference Values in Normal Experimental Animals and Normal Humans","author":"Mitruka BM","year":"1981"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"S234","DOI":"10.1016\/S0022-5347(18)38133-3","article-title":"Phase 1, double\u2010blind, placebo\u2010controlled study in healthy male subjects to investigate the safety, tolerability, and pharmacokinetics of DA\u20108159","volume":"171","author":"Padma\u2010Nathan H","year":"2004","journal-title":"J Urol"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90195-3"},{"key":"e_1_2_9_27_1","first-page":"661","article-title":"Udenafil, a long\u2010acting PDE 5 inhibitor for erectile dysfunction","volume":"7","author":"Salem EA","year":"2006","journal-title":"Curr Opin Investg Drugs"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.238"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(02)00397-7"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10482"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1211\/0022357044904"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.444"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(99)00349-4"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1975184377"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10427"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0707192","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0707192","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0707192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T04:57:59Z","timestamp":1697086679000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0707192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1038\/sj.bjp.0707192"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0707192","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}